Printer Friendly

IMMUNOMEDICS REPORTS PROMISING LYMPHOMA THERAPY RESULTS; CLINICAL FINDINGS PRESENTED AT ANNUAL NUCLEAR MEDICINE MEETING

 IMMUNOMEDICS REPORTS PROMISING LYMPHOMA THERAPY RESULTS;
 CLINICAL FINDINGS PRESENTED AT ANNUAL NUCLEAR MEDICINE MEETING
 MORRIS PLAINS, N.J., June 10 /PRNewswire/ -- Immunomedics, Inc. (NASDAQ: IMMU), scientists presented today at the Society of Nuclear Medicine in Los Angeles the results of the company's ongoing clinical trial treating patients afflicted with certain lymphomas using Immunomedics' LL2 monoclonal antibody labeled with the isotope, iodine-131.
 B-cell lymphoma is diagnosed in about 32,000 new cases annually in the United States, and this number is growing annually with the increasing incidence of lymphoma in AIDS patients. The company reported that in a study of ten lymphomas patients receiving repeated low-doses of the radiolabeled antibody, and who were assessable after therapy, three patients showed a partial remission of up to 7.5 months and three patients showed lesser responses; the other four patients showed no response.
 "A partial remission constitutes more than 50 percent reduction in a tumor for at least one month," stated Carl M. Pinsky, vice president, medical affairs. "One patient had a complete remission, all disease undetectable after therapy, for about one year, and this was after an extremely low dose of the agent," he added. Pinsky explained, "These Phase I/II results are very encouraging, since most of the patients had failed other therapies and since the optimal dose and schedule are still being investigated. A 30 percent partial remission rate in this initial study is therefore quite promising. Trials of this lymphoma therapeutic are in progress or planned at a number of cancer centers in the U.S. and Europe."
 Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections or other diseases.
 -0- 6/10/92
 /CONTACT: Amy Factor of Immunomedics, 201-605-8200/
 (IMMU) CO: Immunomedics, Inc. ST: New Jersey IN: MTC SU:


GK-OS -- NY023 -- 8724 06/10/92 10:15 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 10, 1992
Words:343
Previous Article:BRIGHTER ECONOMIC PICTURE PAINTED BY GROWTH COMPANY CEOs, COOPERS & LYBRAND'S 'TRENDSETTER BAROMETER' REVEALS
Next Article:ULTRAPHONE BASE IN MEXICO EXPANDS WITH ORDERS EXCEEDING $2 MILLION
Topics:


Related Articles
IMMUNOMEDICS ALLOWED PATENT FOR NEW CANCER IMAGING & THERAPY METHODS & AGENTS: FEDERAL GRANT FOR CANCER THERAPEUTIC ALSO AWARDED
IMMUNOMEDICS AWARDED ORPHAN DRUG DESIGNATION FOR LYMPHOMA IMAGING AGENT; MAY DETECT LYMPHOMAS IN HIV-INFECTED PATIENTS
IMMUNOMEDICS REPORTS INITIAL CLINICAL RESULTS OF A NEW CANCER THERAPEUTIC; ANTIBODY HUMANIZATION PROGRAM ALSO ADVANCES
IMMUNOMEDICS REPORTS LYMPHOMA IMAGING AND THERAPY TEST RESULTS POSITIVE PHASE II STAGING AND THERAPY FINDINGS
IMMUNOMEDICS REPORTS ON LYMPHOMA IMAGING AND THERAPY PROGRESS AT CANCER CONFERENCE
IMMUNOMEDICS MAKES ADVANCES IN ANTIBODY RECONSTRUCTION AND HUMANIZATION; PROGRESS IN CANCER THERAPY PROGRAMS REPORTED
IMMUNOMEDICS REPORTS PROGRESS WITH CANCER THERAPEUTIC PROGRAM; EIGHT ABSTRACTS PRESENTED AT THE SOCIETY OF NUCLEAR MEDICINE CONFERENCE
Patent awarded to Immunomedics for lymphoma treatment licensed to Amgen.
Millennium Announces Preliminary Phase I and Phase II Findings of VELCADE(TM) (Bortezomib) For Injection in Studies of Non-Hodgkin's Lymphoma and...
Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters